|
Pemafibrate
Pemafibrate, sold under the brand namd Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals Kowa may refer to: * KOWA-LP, an defunct independent, non-commercial radio station in Olympia, Washington, USA * Kōwa (Heian period) (康和), a Japanese era name for years spanning 1099 to 1103 * Kōwa (Muromachi period) (弘和), a Japanese era .... In July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan. , pharmacodia.com References {{PPAR modulators Fibrates Benzoxazoles ...[...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
PPAR Agonist
PPAR agonists are drugs which act upon the peroxisome proliferator-activated receptor. They are used for the treatment of symptoms of the metabolic syndrome, mainly for lowering triglycerides and blood sugar. Classification PPAR-alpha and PPAR-gamma are the molecular targets of a number of marketed drugs. The main classes of PPAR agonists are: PPAR-alpha agonists An endogenous compound, 7(S)-Hydroxydocosahexaenoic Acid (7(S)-HDHA), which is a Docosanoid derivative of the omega-3 fatty acid DHA was isolated as an endogenous high affinity ligand for PPAR-alpha in the rat and mouse brain. The 7(S) enantiomer bound with micromolar affity to PPAR alpha with 10 fold higher affinity compared to the (R) enantiomer and could trigger dendritic activation. PPARα (alpha) is the main target of fibrate drugs, a class of amphipathic carboxylic acids (clofibrate, gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate). They were originally indicated for cholesterol disorders and more recently ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |